On June 8, 2026, Vor Biopharma Inc. announced that RemeGen Co., Ltd. received conditional approval from the NMPA for telitacicept for the treatment of adult patients with IgA nephropathy and approval from the NMPA for telitacicept for the treatment of adult patients with Sjögren’s disease in China.
